Fri, Sep 19, 2014, 6:52 AM EDT - U.S. Markets open in 2 hrs 38 mins

Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • insm_truth_teller insm_truth_teller May 19, 2013 8:24 AM Flag

    A couple of

    terry_insm • May 8, 2013 3:07 PM
    Arikace and...

    A couple of points on Arikace
    Arikace offers the advantage of time(is money) over current regimes. Currently TOBI take 40 minutes and then additional time to clean the device, where Arikace takes 13 min to administer. Many patients take a couple of hours with therapy for CF.TOBI nebulizer is big bulky and a plug in, Arikaces nebulizer is battery powered and small. Compliance will be better with Arikaces regime The TOBI podhaler is better and will be able to compete even with 2 treatments.-dry powder and uses batteries, its effectiveness slightly worse than standard TOBI

    I don't know if Arikace will display superiority but there is competition from the above TOBI podhaler and generic TOBI in late 2014. Insmed will be up against pharma giants Gilead and Novartis (who may just take them out if superiority and acceptance eventually comes. A buyout would happen before market penetration would be seen. Either way big pharma would know before most anyone else
    more later

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Who cares about the TOBI podhaler and generic TOBI if the predominat strains of Ps aeruginosa are TOBI resistant, for which there is clear evidence, as mentioned by WL in conference calls? I would be willing to bet that there will be clear superiority of Arikace over tobramycin in whatever form of delivery . What matters is antibiotic/pathogen interactions. Cost then becomes immaterial. Efficacy is what matters.

    • terry_insm • May 8, 2013 3:07 PM
      Arikace and...

      A couple of points on Arikace
      Arikace offers the advantage of time(is money) over current regimes. Currently TOBI take 40 minutes and then additional time to clean the device, where Arikace takes 13 min to administer. Many patients take a couple of hours with therapy for CF.TOBI nebulizer is big bulky and a plug in, Arikaces nebulizer is battery powered and small. Compliance will be better with Arikaces regime The TOBI podhaler is better and will be able to compete even with 2 treatments.-dry powder and uses batteries, its effectiveness slightly worse than standard TOBI

      I don't know if Arikace will display superiority but there is competition from the above TOBI podhaler and generic TOBI in late 2014. Insmed will be up against pharma giants Gilead and Novartis (who may just take them out if superiority and acceptance eventually comes. A buyout would happen before market penetration would be seen. Either way big pharma would know before most anyone else
      more later

 
INSM
13.18-0.11(-0.83%)Sep 18 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.